Myriad Genetics sells its prenatal testing business to boost liquidity, but losses persist. Click here to read this latest analysis of MYGN stock.
Myriad and SOPHiA partner with AstraZeneca to apply PrGIS genomic instability scoring in prostate cancer trials, advancing HRD companion diagnostics. Read more here.
The recent update to fair value, from US$3.37 to US$3.91 per share for Myriad Genetics, reflects a recalibration of what analysts think the stock could be worth. This shift sits alongside Street price targets that range widely from US$2 to US$8, with ratings spread from Underweight to Buy, which leaves you with a broad spectrum of risk and return views to consider. As you read on, you will see how these moving targets shape the evolving Myriad Genetics story and what to watch next. Stay...
Myriad Genetics is back in focus after a sharp reset in analyst price targets, with the modelled fair value estimate moving from about US$6.25 to roughly US$3.37, a cut of close to 46%. The shift lines up with more cautious Street commentary that concentrates on execution risk, profitability, and the impact of reduced FY26 guidance on how the stock is valued. As you read on, you will see how to interpret these updates and how to follow the evolving narrative around Myriad Genetics. Stay...
Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.
SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executive Vice President - Commercial, effective September 16, 2026. Vishal has served as the SVP of Product at Myriad for the past year. He has deep understanding of molecular diagnostics and oncology as well as extensive business and commercial leadership experience from his prior roles
Detailed price information for Blink Charging Company (BLNK-Q) from The Globe and Mail including charting and trades.
Myriad Genetics (MYGN) has an average rating of hold and mean price target of $3.37, according to an
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers.
Check out the companies making headlines yesterday:
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 6.2% in the afternoon session after Piper Sandler double-downgraded the stock to Underweight, stating that major strategic action is likely needed.
Myriad Genetics (NASDAQ:MYGN) shares fell 7. 1% in pre-market trading to $2.
SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST. The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at investor.myriad.com. About Myriad Genetics Myriad Genetics is
A number of stocks fell in the afternoon session after shares across biotech and big pharma cooled further as traders continued to secure profits following the extraordinary run. The sector had jumped after Phase 3 results for Moderna’s individualized neoantigen mRNA therapy, intismeran, used with Merck’s Keytruda — the first positive late-stage readout for an mRNA-based cancer vaccine over Keytruda alone. With no fresh clinical or regulatory catalyst to extend the advance, the tape has shifted
This is the newest page. Registered accounts read further back.